







A**GFAP**







hippocampus

piriform cortex

PS19/AQP4KO
(control)PS19/AQP4KO
(TGN-073)**B****Iba1**

hippocampus

piriform cortex

PS19/AQP4KO
(control)PS19/AQP4KO
(TGN-073)**Supplemental Figure 3 Loss of AQP4 abolishes the therapeutic effects of TGN-073 on gliosis in PS19 mice.**

(A) Representative images of the hippocampus and piriform cortex from 9-month-old PS19/AQP4KO mice treated with or without TGN-073 for 3 months along with untreated wildtype mice, stained for GFAP. Scale bar, 500 μ m. Quantification of GFAP positive area (%) in hippocampus or entorhinal (EC) /piriform cortex is shown. One-way ANOVA with Tukey's post hoc test. N=3-8 mice/group. Multiple sections per mouse were analyzed and averaged. (B) Representative images of the hippocampus from 9-month-old PS19/AQP4KO mice treated with or without TGN-073 for 3 months along with untreated wildtype mice, stained for Iba1. Scale bar, 500 μ m. Quantification of Iba1 positive area (%) in hippocampus or entorhinal (EC) /piriform cortex is shown. One-way ANOVA with Tukey's post hoc-test. N=3-8 mice/group. Multiple sections per mouse were analyzed and averaged.